Tubingen, Germany

Isabelle Ehnes

USPTO Granted Patents = 1 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Isabelle Ehnes

Introduction

Isabelle Ehnes is a notable inventor based in Tubingen, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of novel antigen binding proteins. Her work focuses on improving therapeutic options for diseases such as leukemia.

Latest Patents

Isabelle Ehnes holds a patent for "Anti-FLT Antigen Binding Proteins." This invention provides novel human fins related to tyrosine kinase 3 (FLT) antigen binding proteins, including antibodies with enhanced FLT binding affinity and anti-tumor activity. The FLT antibodies were generated through mutation of a parent FLT antibody and were rigorously tested in both in vitro binding assays and in vivo mouse tumor models, as well as in human patient tumor samples. The antibodies are available as monospecific constructs or in a bispecific FLT×CD antibody format, demonstrating excellent target affinity and tumor cell killing capabilities. The invention also encompasses methods for producing these antigen binding proteins, along with nucleic acids encoding them, vectors for their expression, and host cells. Furthermore, it relates to methods for treating or diagnosing diseases like leukemia using the FLT antigen binding proteins.

Career Highlights

Throughout her career, Isabelle has worked with prestigious institutions, including the Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts and Eberhard Karls Universität Tübingen. Her research has significantly advanced the understanding and treatment of cancer.

Collaborations

Isabelle has collaborated with various professionals in her field, including Gundram Jung, enhancing the impact of her research through teamwork and shared expertise.

Conclusion

Isabelle Ehnes is a pioneering inventor whose work on anti-FLT antigen binding proteins has the potential to transform cancer treatment. Her contributions to biotechnology reflect her commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…